• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ascendis Pharma ADR (NQ: ASND )

    124.81 +1.99 (+1.62%)
    Streaming Delayed Price Updated: 11:51 AM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Ascendis Pharma ADR

    < Previous 1 2 3 4 5 6 7 Next >
    10 Biggest Price Target Changes For Monday
    Wells Fargo raised the price target on Laredo Petroleum, Inc. (NYSE: LPI) from $72 to $113. Laredo Petroleum shares fell 2.8% to $71.00 in pre-market trading. 
    Via Benzinga
    Ascendis Pharma's Hypoparathyroidism Trial Meets Primary, Secondary Endpoints
    Ascendis Pharma A/S (NASDAQ: ASND) announced topline data from its Phase 3 PaTHway Trial of TransCon PTH in adults with hypoparathyroidism (HP), a condition in... 
    Via Benzinga
    7 Biotech Stocks With Key Catalysts in March
    These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways. 
    Via InvestorPlace
    Expert Ratings For Ascendis Pharma
    Within the last quarter, Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total... 
    Via Benzinga
    The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO
    Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus NuCana Discontinues Biliary Tract Cancer Study Following Futility Analysis... 
    Via Benzinga
    Where Ascendis Pharma Stands With Analysts
    Over the past 3 months, 4 analysts have published their opinion on Ascendis Pharma (NASDAQ:ASND) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
    Via Benzinga
    Where Ascendis Pharma Stands With Analysts
    Analysts have provided the following ratings for Ascendis Pharma (NASDAQ:ASND 
    Via Benzinga
    Earnings Scheduled For March 2, 2022
    Companies Reporting Before The Bell • SIGNA Sports United (NYSE:SSU) is expected to report quarterly loss at $0.04 per share on revenue of $283.61 million. •... 
    Via Benzinga
    Analyst Ratings For Ascendis Pharma
    Analysts have provided the following ratings for Ascendis Pharma (NASDAQ:ASND 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022
    Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,... 
    Via Benzinga
    Pfizer Dives After FDA Rejects Its OPKO-Partnered Rare Disease Treatment
    Pfizer stock tumbled after the FDA rejected an OPKO-partnered drug. 
    Via Investor's Business Daily
    Ascendis Pharma's Growth Hormone Deficiency Med Scores European Approval
    The European Commission (EC) has granted marketing authorization to Ascendis Pharma A/S's (NASDAQ: ASND) Lonapegsomatropin (developed under the name TransCon hGH).... 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2022
    Upgrades According to Mizuho, the prior rating for Murphy Oil Corp (NYSE:MUR) was changed from Neutral to Buy. In the fourth quarter, Murphy Oil showed an EPS of $0.40,... 
    Via Benzinga
    The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial
    Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Connect Biopharma Atopic Dermatitis Treatment Aces Mid-stage Study But Lack... 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2022
    Upgrades For Canada Goose Holdings Inc (NYSE: 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021
    Upgrades According to Deutsche Bank, the prior rating for Goodyear Tire & Rubber Co (NASD... 
    Via Benzinga
    Ascendis' Hypoparathyroidism Candidate Shows Durable Benefit At 84 Weeks
    Ascendis Pharma A/S (NASDAQ: ASND) announced topline results from Week 84 of its Phase 2 PaTH Forward Trial of its TransCon PTH candidate hypoparathyroidism (HP).... 
    Via Benzinga
    10 Biggest Price Target Changes For Monday
    Keybanc boosted the price target on Netflix, Inc. (NASDAQ: NFLX) from $690 to $725. Netflix shares rose 0.2% to $683.90 in pre-market trading. Piper Sandler raised the price... 
    Via Benzinga
    Ascendis Pharma A/S (ASND) Q3 2021 Earnings Call Transcript
    ASND earnings call for the period ending September 30, 2021. 
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2021
    Upgrades For Iridium Communications Inc (NASDAQ:IRD... 
    Via Benzinga
    The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs, And More
    Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Here are the key catalysts that could move stocks in the unfolding... 
    Via Talk Markets
    Exposures Product Safety
    The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
    Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Positive tidings from Merck & Co... 
    Via Benzinga
    Exposures Product Safety
    Pfizer's Growth Hormone Candidate FDA Review Pushed By 3 Months
    Pfizer Inc's (NYSE: PFE) effort to defend its growth hormone franchise against a new, more convenient competitor has hit a snag. The FDA has pushed back... 
    Via Benzinga
    Exposures Product Safety
    Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates
    August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New... 
    Via Benzinga
    The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22) Acceleron Pharma Inc. (... 
    Via Benzinga
    Exposures COVID-19
    The Week Ahead In Biotech (Aug. 29- Sept. 4): Merck's Keytruda Regulatory Decision, Stray Earnings On Tap In A Light Week
    Biopharma stocks had a strong start to the week amid optimism generated by full approval accorded to the mRNA vaccine developed by Pfizer, Inc. and BioNTech SE. The stocks subsequently moved back and... 
    Via Talk Markets
    The Week Ahead In Biotech (Aug. 29- Sept. 4): Merck's Keytruda Regulatory Decision, Stray Earnings On Tap In a Light Week
    Biopharma stocks had a strong start to the week amid optimism generated by full approval accorded to the mRNA vaccine developed by Pfizer, Inc. (NYSE: PFE) and BioNTech SE (... 
    Via Benzinga
    The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7) Adial Pharmaceuticals, Inc... 
    Via Benzinga
    Exposures Product Safety
    Ascendis Pharma A/S (ASND) Q2 2021 Earnings Call Transcript
    ASND earnings call for the period ending June 30, 2021. 
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31) AC Immune SA (NASDAQ: ACIU... 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.